ライフサイエンスコーパス: differentiated thyroid cancer

1 uce recurrences and improve survival in well-differentiated thyroid cancer.

2 d remnant or residual tumor in patients with differentiated thyroid cancer.

3 data were reviewed in 347 patients with well-differentiated thyroid cancer.

4 uman Thyroglobulin (TG), a protein marker of differentiated thyroid cancer.

5 SDHD in autophagy-associated pathogenesis of differentiated thyroid cancer.

6 or metastatic, radioactive iodine-refractory differentiated thyroid cancer.

7 erminate nodules that may be associated with differentiated thyroid cancer.

8 TT or lobectomy is often needed to diagnose differentiated thyroid cancer.

9 th progressive radioactive iodine-refractory differentiated thyroid cancer.

10 th progressive radioactive iodine-refractory differentiated thyroid cancer.

11 nizations for the treatment of patients with differentiated thyroid cancer.

12 vels to predict future risk of recurrence of differentiated thyroid cancer.

13 s been largely extrapolated from staging for differentiated thyroid cancer.

14 s of (123)I and (131)I whole-body imaging in differentiated thyroid cancer.

15 logical features of human RAS-driven, poorly differentiated thyroid cancers.

16 ancers had significantly more CSCs than well-differentiated thyroid cancers.

17 ons in the matched normal tissues or in well-differentiated thyroid cancers.

18 rapidly progressive, radioiodine-refractory differentiated thyroid cancers.

19 herapeutic option for patients with advanced differentiated thyroid cancers.

20 is also a marker of the extent of disease in differentiated thyroid cancers.

21 ge of the molecular pathogenesis of advanced differentiated thyroid cancer and discuss findings from

22 xpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate.

23 downregulation was associated with advanced differentiated thyroid cancer and higher mortality.

24 al growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with agg

25 which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue.

26 h a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radio

27 included cohorts of persons treated for well-differentiated thyroid cancer and persons with no surger

28 hyroid or recurrent disease in patients with differentiated thyroid cancer and to evaluate which of t

29 ovides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases.

30 ration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatm

31 nclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 c

32 Differentiated thyroid cancers are typically iodine-avid

33 lifetime cancer risks for patients with well differentiated thyroid cancers as part of families with

34 panib in an expanded cohort of patients with differentiated thyroid cancer, as well as in cohorts of

35 a is an uncommon and occasionally aggressive differentiated thyroid cancer associated with increased

36 Among patients treated for well-differentiated thyroid cancer at hospitals in the Nation

37 the role of anthropometric risk factors for differentiated thyroid cancer at the time of diagnosis a

38 The study included 761 adults diagnosed with differentiated thyroid cancer before 35 years of age bet

39 uded 633 young women who were diagnosed with differentiated thyroid cancer before 35 years of age bet

40 In high-activity radioiodine therapies for differentiated thyroid cancer, blood dosimetry has been

41 historically proven ineffective in advanced differentiated thyroid cancers, but the realisation that

42 Hurthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggres

43 of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and he

44 tal thyroidectomy in high-risk patients with differentiated thyroid cancer (containing follicular his

45 DECISION trial of sorafenib in patients with differentiated thyroid cancer demonstrated significantly

46 demonstrated the importance of aneuploidy in differentiated thyroid cancer development.

47 n clinical trials for radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroi

48 d-type (BRAF-WT) in patients with metastatic differentiated thyroid cancer (DTC) and poorly different

49 Since thyroglobulin, no new blood tests for differentiated thyroid cancer (DTC) have been introduced

50 Differentiated thyroid cancer (DTC) incidence has been r

51 The incidence of differentiated thyroid cancer (DTC) is increasing.

52 Although differentiated thyroid cancer (DTC) is typically an indo

53 Patients with metastatic differentiated thyroid cancer (DTC) may be prepared usin

54 ent side effects of radioiodine treatment in differentiated thyroid cancer (DTC) patients.

55 aration for the detection of metastases from differentiated thyroid cancer (DTC) using (131)I WB imag

56 Several susceptibility loci of differentiated thyroid cancer (DTC) were identified by p

57 ge, single-center cohort of patients who had differentiated thyroid cancer (DTC) with that of a match

58 merous staging and scoring systems exist for differentiated thyroid cancer (DTC), but all harbor limi

59 ody (TgAb) measurements in the management of differentiated thyroid cancer (DTC), taking into conside

60 Differentiated thyroid cancer (DTC), with a rapidly incr

61 nd approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

62 ET-PTC expedites optimal initial surgery for differentiated thyroid cancer, facilitating succinct def

63 Treatment of differentiated thyroid cancer has been studied for many

64 e reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications

65 I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis beca

66 ly 30% of patients with advanced, metastatic differentiated thyroid cancer have radioiodine-refractor

67 C), and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality, pa

68 lar thyroid cancer is the second most common differentiated thyroid cancer histological type and has

69 lasm." Permanent histology demonstrated well-differentiated thyroid cancer in 6 of these 28 patients

70 The optimal treatment of differentiated thyroid cancer in pediatric patients cont

71 Differentiated thyroid cancer in young patients is assoc

72 T) imaging in the follow-up of patients with differentiated thyroid cancer is an important developmen

73 The extent of primary thyroidectomy for differentiated thyroid cancer is controversial.

74 The incidence of differentiated thyroid cancer is increasing greatly in h

75 Differentiated thyroid cancer is the most common endocri

76 Differentiated thyroid cancer is the most frequent subty

77 optimal treatment for younger patients with differentiated thyroid cancer may differ from that for a

78 Unlike differentiated thyroid cancer, nodal metastases predict

79 sTC was defined by histological differentiated thyroid cancer of 1 cm or more and/or lym

80 .7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or whether the effects of

81 rican Joint Committee on Cancer stage I well-differentiated thyroid cancer patients treated with radi

82 and follow-up (124)I PET/CT data on BMs from differentiated thyroid cancer patients were retrospectiv

83 (124)I PET/CT images from differentiated thyroid cancer patients were retrospectiv

84 ve developed for the long-term monitoring of differentiated thyroid cancer patients.

85 Poorly differentiated thyroid cancer (PDTC) and anaplastic thyr

86 ancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).

87 fferentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

88 Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroi

89 t recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of th

90 Children with differentiated thyroid cancer present with more advanced

91 dioiodine in the evaluation of patients with differentiated thyroid cancer, radiolabeled anti-CEA MAb

92 ease in the proportion of patients with well-differentiated thyroid cancer receiving radioactive iodi

93 cebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

94 Guidelines for the management of differentiated thyroid cancer should continue to reflect

95 M1 mRNA expression was higher in TNM stage I differentiated thyroid cancers than in stage II and III

96 ne-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within

97 nses in patients with advanced or metastatic differentiated thyroid cancer that is progressive.

98 y in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to rad

99 that progresses from the highly curable well-differentiated thyroid cancers to the universally fatal

100 se in a cohort of 189,219 patients with well-differentiated thyroid cancer treated at 981 hospitals a

101 All available data regarding differentiated thyroid cancer treatment in children are

102 he blood in patients with surgically treated differentiated thyroid cancer undergoing their first rad

103 proach generally applied in the treatment of differentiated thyroid cancer was assessed using (124)I

104 The incidence of well differentiated thyroid cancer (WDTC) is increasing in th

105 opulation-based cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with

106 e clinical records of 284 patients with well-differentiated thyroid cancer were reviewed.

107 ased detailed management recommendations for differentiated thyroid cancer, which primarily addressed

108 In patients with newly diagnosed differentiated thyroid cancer who had undergone thyroide

109 o I-131 treatment for patients with advanced differentiated thyroid cancer will provide critical info

110 dvanced or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of motesanib d

111 sed on 16 studies (n = 291796), treatment of differentiated thyroid cancer with radioactive iodine is